Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Wake Forest University National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00296049 |
RATIONALE: Antibiotics, such as daptomycin and vancomycin, may be effective in treating bacteria in the blood. It is not yet known whether daptomycin is more effective than vancomycin in treating bacteria in the blood in patients with neutropenia caused by chemotherapy.
PURPOSE: This randomized clinical trial is studying daptomycin to see how well it works compared with vancomycin in treating bacteria in the blood in patients with neutropenia caused by chemotherapy.
Condition | Intervention |
---|---|
Cancer-Related Problem/Condition Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific |
Drug: daptomycin Drug: vancomycin |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Open Label |
Official Title: | An Open-Label, Pilot Study of Daptomycin vs. Vancomycin for Treatment of Gram-Positive Bacteremia in Neutropenic Cancer Patients |
Estimated Enrollment: | 30 |
Study Start Date: | July 2005 |
OBJECTIVES:
Primary
OUTLINE: This is an open-label, randomized, pilot study. Patients are randomized to 1 of 2 treatment arms.
After completion of study therapy, patients are followed at 6 and 12 weeks.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Two or more blood cultures positive for gram-positive cocci
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, North Carolina | |
Wake Forest University Comprehensive Cancer Center | |
Winston-Salem, North Carolina, United States, 27157-1096 |
Study Chair: | Kevin High, MD | Wake Forest University |
Study ID Numbers: | CDR0000466308, CCCWFU-98804, CUBIST-CCCWFU-98804, CCCWFU-BG04-494 |
Study First Received: | February 23, 2006 |
Last Updated: | October 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00296049 History of Changes |
Health Authority: | United States: Federal Government |
unspecified adult solid tumor, protocol specific infection neutropenia unspecified childhood solid tumor, protocol specific |
Daptomycin Anti-Bacterial Agents Neutropenia Vancomycin Bacteremia |
Daptomycin Anti-Infective Agents Anti-Bacterial Agents |
Therapeutic Uses Vancomycin Pharmacologic Actions |